Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science [PDF]
Clinical and Translational ScienceIbrexafungerp is a first‐in‐class triterpenoid antifungal that targets β‐(1,3)‐glucan synthase in fungal cell wall development. It is indicated for vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (RVVC) in adult and post‐menarchal ...
Adelynne H. Walley +3 more
doaj +5 more sources
Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections [PDF]
Journal of Fungi, 2022 Molds are ubiquitous in the environment, and immunocompromised patients are at substantial risk of morbidity and mortality due to their underlying disease and the resistance of pathogenic molds to currently recommended antifungal therapies.
David A. Angulo +9 more
doaj +12 more sources
Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: A meta-analysis of randomized controlled trials [PDF]
HeliyonBackground: This study aims to evaluate the efficacy and safety associated with ibrexafungerp in the treatment of vulvovaginal candidiasis infection patients.
Fei Lin
exaly +8 more sources
Candida glabrata Prosthetic Joint Infection Managed with Ibrexafungerp [PDF]
Journal of FungiWe report a case of a triazole and echinocandin-resistant C. glabrata right shoulder prosthetic joint infection in a 60-year-old woman. The patient underwent surgery and received the novel triterpenoid antifungal agent ibrexafungerp.
Ella Nadarevic +2 more
doaj +5 more sources
Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata [PDF]
Frontiers in Cellular and Infection Microbiology, 2021 Systemic infections caused by Candida species are an important cause of morbidity and mortality among immunocompromised and non-immunocompromised patients.
Ahmed Gamal, Mahmoud A Ghannoum
exaly +6 more sources
Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor [PDF]
Journal of Fungi (Basel, Switzerland), 2021 Ibrexafungerp (formerly SCY-078 or MK-3118) is a first-in-class triterpenoid antifungal or “fungerp” that inhibits biosynthesis of β-(1,3)-D-glucan in the fungal cell wall, a mechanism of action similar to that of echinocandins.
Sabelle Jallow, Nelesh P Govender
exaly +7 more sources
Drug Design, Development and Therapy, 2023 Nancy A Phillips, Maria Rocktashel, Lena Merjanian Department Obstetrics, Gynecology & Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USACorrespondence: Nancy A Phillips, Department Obstetrics, Gynecology ...
Phillips NA, Rocktashel M, Merjanian L
exaly +7 more sources
A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin [PDF]
Journal of FungiThis mini-review summarizes the clinical outcomes and antifungal susceptibility results, where available, for three new antifungals, including fosmanogepix, ibrexafungerp, and rezafungin, against Candida isolates cultured from patients in clinical trials.
Ana Espinel-Ingroff +1 more
doaj +4 more sources
Tn-seq screens in Candida glabrata treated with echinocandins and ibrexafungerp reveal pathways of antifungal resistance and cross-resistance [PDF]
mSphereCandida glabrata (also known as Nakaseomyces glabratus) is the second most common cause of candidiasis, next to Candida albicans, and is rising in prevalence due to intrinsic and acquired mechanisms of antifungal resistance.
Timothy J. Nickels, Kyle W. Cunningham
doaj +3 more sources
Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections [PDF]
Antibiotics, 2020 Candida auris is an emerging multidrug-resistant fungal pathogen reported worldwide. Infections due to C. auris are usually nosocomial and associated with high rates of fluconazole resistance and mortality.
Mahmoud Ghannoum +11 more
doaj +2 more sources